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 Objectives: To evaluate the efficacy and safety, we conducted a randomized 
phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly 
patients with non-squamous non-small cell lung cancer (NSqNSCLC).  
 Patients and methods: The eligibility criteria were as follows: NSqNSCLC, no 
prior therapy, stage IIIB/IV disease or postoperative recurrence, age: ≥75 years, 
performance status (PS): 0-1, and adequate bone marrow function. The patients were 
randomly assigned (1:1 ratio) to receive Pem or Pem+Bev. The primary endpoint was 
progression-free survival (PFS). The secondary endpoints were the response rate, OS, 
toxicities, and cost-effectiveness.  
 Results: Forty-one patients were enrolled and 40 (20 from each group) were 
assessable. Their characteristics were as follows: male/female=23/17; median age 
(range)=78 (75-83); stage IIIB/IV/postoperative recurrence=1/30/9; PS 0/1=11/29. All 
cases involved adenocarcinoma. There was no significant intergroup difference in PFS 
and the median PFS (95% confidence interval) values of the Pem and Pem+Bev groups 
were 5.4 (3.0-7.4) and 5.5 (3.6-9.9) months, respectively (p=0.66). The response rate 
was significantly higher in the Pem+Bev group (15% vs. 55%, p=0.0146), and there 
was no significant difference in OS (median: 16.0 vs. 16.4 months, p=0.58). Grade 3 
and 4 leukopenia, neutropenia, and thrombocytopenia were seen in 10 and 30, 20 and 55, 
and 5 and 5 cases, respectively. Drug costs were higher in the Pem+Bev group (median: 
1,522,008 vs. 3,368,428 JPY, p=0.01). No treatment-related deaths occurred.  
 Conclusions: Adding Bev to Pem did not result in improved survival in the 
elderly NSqNSCLC patients. Compared with Pem+Bev, Pem monotherapy had similar 
effects on survival, a more favorable toxicity profile, and was more cost-effective in 
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elderly NSqNSCLC patients. Pem monotherapy might be one of the optional regimen 




Lung cancer is the leading cause of cancer death worldwide. It is also the 
leading cause of cancer death in Japan, with 78,000 estimated deaths from lung cancer 
occurring in 2017 (20.6% of all cancer deaths) (1), and non-small cell lung cancer 
(NSCLC) accounts for 80% of cases of lung cancer. Due to the aging of the Japanese 
population, the number of elderly patients with NSCLC in Japan is increasing. The 
frequency of severe toxicities is high in elderly patients treated with chemotherapy, even 
those that appear to have normal organ function (13). In elderly patients with advanced 
NSCLC, vinorelbine was reported to result in improved survival compared with 
supportive care alone (14), and docetaxel achieved even better survival outcomes than 
vinorelbine (15). Chemotherapy is approved as a treatment for elderly patients with 
NSCLC, and docetaxel monotherapy and vinorelbine monotherapy are recognized as 
standard regimens. However, effective and less toxic chemotherapy regimens are 
needed to improve the outcomes of elderly patients.  
Pemetrexed is an antifolate, antitumor agent, which exerts its effects by 
interrupting folate-dependent metabolic processes that are essential for cell replication. 
It targets thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide 
formyltransferase (2). Compared with docetaxel monotherapy, pemetrexed exhibited 
equivalent efficacy against NSCLC and had significantly fewer side effects, and it was 
confirmed to be especially effective against non-squamous NSCLC (NSqNSCLC) (3). 
Subset analysis revealed that elderly patients aged ≥70 years who received pemetrexed 
demonstrated longer time to progression (4.6 vs. 2.9 months) and overall survival (9.5 
vs. 7.7 months) values than those treated with docetaxel (16). Thus, it seems that the 
milder toxicities of pemetrexed may lead to more favorable outcomes among elderly 
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NSCLC patients.  
Bevacizumab, a recombinant humanized IgG1 monoclonal antibody that 
binds to vascular endothelial growth factor, has become the focus of therapeutic 
interventions aimed at blocking tumor angiogenesis and elevating the blood levels of 
chemotherapeutic drugs by promoting tumor vascular stabilization (10-12). 
Bevacizumab has been approved for use in combination with the standard 
platinum-based chemotherapy or as a maintenance therapy after chemotherapy during 
the treatment of NSCLC patients without driver mutations (7-9), and it was found to 
significantly prolong overall survival and progression-free survival when added to 
first-line platinum-based chemotherapy in patients with advanced NSCLC (17). When 
added to the standard chemotherapy, there is a possibility that bevacizumab bring 
beneficial effects after excluding high-risk patients with squamous cell carcinoma or 
hemoptysis.  
Therefore, compared with the standard chemotherapy 
pemetrexed/bevacizumab combination chemotherapy is considered to be a potentially 
useful treatment for elderly patients with NSqNSCLC. So, we conducted a randomized 
phase II study of pemetrexed versus pemetrexed plus bevacizumab treatment for elderly 
patients with NSqNSCLC. Both regimens were continued until tumor progression or 
unacceptable toxicities occurred.  
 
PATIENTS AND METHODS 
 The study protocol was reviewed and approved by the protocol committee of 
the Lung Oncology Group in Kyushu (LOGiK), and the ethics committee of each 
institution. Written informed consent was obtained from all study participants. This 
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study was an independent collaborative (unsponsored) group study. It was registered at 
the University Hospital Medical Information Network (UMIN) in Japan (registration 
number: UMIN000008771). 
 
Study design and patients 
LOGIK1201 was initially designed as a phase II randomized trial of 
pemetrexed versus pemetrexed plus bevacizumab as first-line treatments for patients 
with NSqNSCLC. 
The eligibility criteria for this study were as follows: having a histologically 
and/or cytologically confirmed diagnosis of NSqNSCLC; having not received any 
previous chemotherapy except for molecularly targeted therapy or postoperative 
chemotherapy that was administered more than 6 months ago; not being indicated for 
radical radiotherapy; having clinical stage IIIB or IV disease or postoperative 
recurrence; not having any other active malignancies; being aged ≥75 years old; having 
an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤1; 
having adequate bone marrow function (a leukocyte count of ≥4,000/µl, a hemoglobin 
level of ≥9.0 g/dl, and a platelet count of ≥10.0 x 104/µl); having alanine 
aminotransferase (ALT) and aspartate transaminase (AST) levels of <100 IU/l, a serum 
bilirubin level of ≤1.5 mg/dl, a serum creatinine level of ≤1.5 mg/dl, a urinary protein 
score of ≤1+, and an arterial O2 pressure of ≥60 Torr or an SpO2 of ≥90%; having a 
lesion that could be assessed using the Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1; providing written informed consent; and having a life 
expectancy of >3 months. The exclusion criteria were as follows: having a symptomatic 
metastatic brain tumor, hemoptysis, arterial or venous thromboemboli, uncontrolled 
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hypertension, perforation of the digestive tract, a severe tracheoesophageal fistula, 
peritoneal inflammation, congenital hemorrhagic diathesis, a coagulation system 
disorder, uncontrolled diabetes, emergency superior vena cava syndrome, symptomatic 
pericardial effusion, interstitial pneumonia (as determined by a chest X-ray), or medical 
problems that were severe enough to prevent compliance with the protocol; having 
undergone an operation within the last 28 days; or being scheduled for planned 
radiotherapy during the bevacizumab therapy. The threshold age of 75 for elderly 
patients was decided in our group because that the patients from 70 to 74 years old 
could receive platinum doublet for first line chemotherapy.  
 
Assessments 
 Before treatment, the patients’ complete medical histories were taken, and all 
patients underwent physical examinations, chest X-ray examinations, chest and 
abdominal computed tomography (CT) scans, radionuclide bone or positron emission 
tomography (PET)-CT scans, brain magnetic resonance imaging, and 
electrocardiography, as well as assessments of their complications, blood cell counts, 
blood biochemistry, urinary protein levels, and epidermal growth factor receptor 
(EGFR) mutations. In the assessment of cost-effectiveness, all of the main and 
supportive treatment drugs and blood infusions were included. Patient responses were 
assessed according to the RECIST, version 1.1. All adverse events were recorded and 
graded according to the Common Terminology Criteria for Adverse Events (CTCAE), 






 The patients were randomly allocated with equal probability (1:1) to receive 
pemetrexed or pemetrexed plus bevacizumab, and were stratified by disease stage 
(IIIB/IV/postoperative recurrence) and sex (male/female). The patients received 
chemotherapy with pemetrexed (500 mg/m2; a 10-minute intravenous infusion; every 21 
days) or pemetrexed plus bevacizumab (15 mg/kg; an intravenous infusion; every 21 
days) until one of the criteria for treatment removal was met, which included disease 
progression based on the investigator’s assessment or symptomatic deterioration; a 
treatment delay of longer than 2 weeks; pemetrexed dose reduction to <400 mg/m2; 
bevacizumab dose reduction to <10 mg/kg; drug-induced interstitial pneumonia; 
bleeding episodes, such as hemoptysis, in the bevacizumab-treated patients; or 
unacceptable toxicity. Treatment was postponed if the patient’s leukocyte count fell to 
<3,500/µl, their neutrophil count fell to <1,500/µl, or their platelet count fell to <10 x 
104/µl; a fever of ≥38.0 °C combined with infection occurred; the patient’s AST/ALT 
level rose to >2.5 times above the upper normal limit; the patient’s serum creatinine 
level increased to >1.5 times above the upper normal limit; heart/lung toxicities of grade 
≥2 occurred; or other toxicities of ≥grade 3, except for hair loss, nausea/vomiting, 
appetite loss, and fatigue, occurred. Dose reduction to a pemetrexed dose of 400 mg/m2 
and/or a bevacizumab dose of 10 mg/kg was performed if any of the following adverse 
events were observed: a neutrophil count of <500/µl, a neutrophil count of <1,000/µl 
with an infra-axillary fever of 37.5 °C (oral cavity: 38.0 °C), a platelet count of <5 x 





 The primary endpoint of this study was progression-free survival, which was 
assessed by an independent review committee. The secondary endpoints included 
overall survival, the tumor response, toxicities, and cost-effectiveness. The expected 
median progression-free survival times of the pemetrexed group (4) and the pemetrexed 
plus bevacizumab group (18) were 3.3 months and 7.4 months, respectively. The 
enrollment period was 5 years long, the follow-up period was 1 year long, the 
significance level was set at 0.2, and the power level was set at 0.8 for the log-rank test. 
Therefore, the estimated required number of patients was more than 32. As some cases 
would be ineligible, the target sample size was set at 40 (20 for each group). In the 
survival analysis, survival curves were produced using the Kaplan-Meier method, and 
the stratified log-rank test, which stratified the data according to the allocation factors 
(disease stage and sex), was used for comparisons between groups. Furthermore, the 
stratified proportional hazards model, which stratified the data according to the 
allocation factors, was used to estimate hazard ratios. The confidence intervals for the 
median survival time and survival rate were computed using the Brookmeyer and 
Crowley method and Greenwood formula, respectively. A stratified multiple logistic 
regression model, which considered the stratified factors, was used for comparisons of 
binary indefinite numbers, including the response rate. The confidence intervals for the 
response rate were computed using the Wilson method. The Wilcoxon rank sum test 
was used for the analysis of cost-effectiveness. In the main analysis, p-values of <0.2 
(two-sided) were defined as statistically significant. In the other analyses, p-values of 
<0.05 (two-sided) were regarded as statistically significant. No adjustments for 





 Forty-one patients from 12 institutions were enrolled and underwent 
randomization (20 to the pemetrexed group and 21 to the pemetrexed plus bevacizumab 
group) in this trial between August 31, 2012, and June 30, 2016. The data cut-off date 
was October 25, 2017. A consort diagram is shown in Supplement Figure 1. Treatment 
was discontinued before the main treatment was administered in one patient in the 
pemetrexed plus bevacizumab group because of drug eruptions caused by the 
premedication. Survival, the response to treatment, and toxicity were evaluated in the 
remaining 40 patients as the full analysis set (FAS). The patients’ baseline demographic 
and clinical characteristics were balanced across the two groups, as shown in Table 1. 
Patients between the ages of 75 and 83 were enrolled, and their median age was 78 
years. All of the tumors were histologically diagnosed as adenocarcinoma.  
 
Treatment administration 
 The median duration of treatment was 3.0 months (range, 0.7 to 14.9 months) 
in the pemetrexed group and 3.9 months (range, 0.9 to 23.6 months) in the pemetrexed 
plus bevacizumab group. A total of 123 cycles of pemetrexed were administered, with 
the median number of cycles administered per patient being 4.5 (range, 1 to 21 cycles), 
and a total of 157 cycles of pemetrexed plus bevacizumab were administered, with the 
median number of cycles administered per patient being 5.5 (range, 2 to 31 cycles). 
Dose reduction was performed in 3 patients (15%) and 13 cycles (11%) in the 
pemetrexed group and in 6 patients (30%) and 16 cycles (10%) in the pemetrexed plus 
bevacizumab group. The reasons for treatment discontinuation included tumor 
progression (n=22, 55%), adverse events (n=7, 18%), treatment postponement for more 
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than 14 days (n=3, 8%), patient refusal (n=2, 5%), and other considerations of the 





The progression-free survival times of the 40 patients are shown in Figure 1A. 
The median duration of the progression-free survival period [95% confidence interval 
(CI)] was 5.4 (3.0-7.4) months in the pemetrexed group and 5.5 (3.6-9.9) months in the 
pemetrexed plus bevacizumab group. There was no significant difference in the 
progression-free survival time between the two groups (p=0.66, log-rank test). 
According to the stratified Cox proportional hazards model, the hazard ratio (95%CI) 
for the pemetrexed plus bevacizumab group versus the pemetrexed group was 0.84 
(0.38-1.86). The 6-month progression-free survival rate (95%CI) was 45.5% 
(21.0-67.1%) in the pemetrexed group and 50.0% (27.1-69.2%) in the pemetrexed plus 
bevacizumab group.  
 
Overall survival 
 The overall survival data for the 40 patients are shown in Figure 1B. The 
median overall survival time (95%CI) was 16.0 (9.0-29.1) months in the pemetrexed 
group and 16.4 (7.9-36.0) months in the pemetrexed plus bevacizumab group. There 
was no significant difference in the overall survival time between the two groups 
(p=0.58, log-rank test). The stratified Cox proportional hazards model indicated that the 
hazard ratio (95%CI) for the pemetrexed plus bevacizumab group versus the 
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pemetrexed group was 0.79 (0.35-1.79). The one-year overall survival rate (95%CI) was 
62.9% (37.2-80.4%) in the pemetrexed group and 74.7% (49.4-88.6%) in the 
pemetrexed plus bevacizumab group. The two-year overall survival rate (95%CI) was 
32.7% (10.4-57.5%) in the pemetrexed group and 40.4% (18.6-61.5%) in the 
pemetrexed plus bevacizumab group.  
 
Response rate 
The median amount of tumor shrinkage (95%CI) was 15.0% (5.2-36.0%) in 
the pemetrexed group and 55.0% (34.2-74.2%) in the pemetrexed plus bevacizumab 
group. The best overall responses in each group were as follows: complete response 
(CR), 0; partial response (PR), 3; stable disease (SD), 11; progressive disease (PD), 4; 
and not evaluable (NE), 2 in the pemetrexed group and CR, 0; PR, 11; SD, 7; PD, 1; and 
NE, 1 in the pemetrexed plus bevacizumab group (Table 2). The best tumor shrinkage 
rate and best overall responses seen in the 39 patients are shown in Supplement Figure 3. 
One patient whose response was NE in the pemetrexed group could not be monitored 
and so was excluded. Intergroup comparisons were conducted using a stratified logistic 
regression model, in which the data were stratified according to disease stage and sex. 
The response rate of the pemetrexed plus bevacizumab group was significantly higher 
than that of the pemetrexed group (p=0.0146).  
 
Safety and adverse events 
 The hematological and non-hematological toxicities experienced by the 
patients in each group are listed in Table 3. Grade 3/4 neutropenia, diarrhea, and 
proteinuria tended to occur more frequently in the pemetrexed plus bevacizumab group 
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than in the pemetrexed group, but the differences were not significant. Oral mucositis 
and hyponatremia were observed significantly higher in the pemetrexed plus 
bevacizumab group compare with pemetrexed group (25% vs. 0%, p=0.047, and 90% 
vs. 50%, p=0.014, respectively). The frequencies of the other toxicities did not differ 
between the two groups. One patient with nasal bleeding of grade 1 was observed in the 




There was no difference in the progression-free survival or overall survival 
time between the two groups. Therefore, the total medication costs (for pemetrexed, 
bevacizumab, and concomitant medication), and the individual costs for pemetrexed, 
bevacizumab, and concomitant medication were calculated for each group, and then 
intergroup comparisons were performed. The total cost of treatment in the pemetrexed 
plus bevacizumab group (median: 3,368,428 Japanese Yen (JPY); range: 1,074,314 to 
18,670,494 JPY) was significantly higher than the total cost of treatment in the 
pemetrexed group (median: 1,522,008 JPY; range: 318,118 to 7,211,480 JPY) (p=0.01). 
As there were no differences in the cost of pemetrexed or the concomitant medication 
between the two groups, the intergroup cost differences were mainly due to the cost of 
bevacizumab.  
 
Relationship between tumor shrinkage and progression-free survival  
 The relationships between the tumor shrinkage rate (during the best tumor 
response) and the progression-free survival rate in the two groups are shown in Figure 2. 
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One patient in the pemetrexed plus bevacizumab group had both a high shrinkage rate 
and a long progression-free survival period. The other patients in the pemetrexed plus 
bevacizumab group tended to have high shrinkage rates, but this did not result in longer 
survival.  
 
Subpopulation analyses of progression-free and overall survival 
In the subpopulation analyses of progression-free and overall survival 
according to sex, age, disease stage, EGFR mutation status, and smoking history, no 
significant differences were detected between the treatment groups (Figure 3). 
 
DISCUSSION 
The present study is the first prospective study to compare the clinical impact 
of pemetrexed plus bevacizumab with that of pemetrexed in NSqNSCLC patients aged 
≥75 years. Compared with pemetrexed treatment, pemetrexed plus bevacizumab did not 
result in a longer progression-free survival period (the primary endpoint). In addition to 
having similar effects on survival to pemetrexed plus bevacizumab, pemetrexed 
monotherapy exhibited a more favorable toxicity profile and was more cost-effective in 
NSqNSCLC patients aged ≥75 years, and so it seems to be a useful treatment option for 
this population.  
The current standard treatments for elderly NSCLC patients are vinorelbine or 
docetaxel, and docetaxel was found to be superior in a comparison between these two 
agents (6, 14). About combination chemotherapy for elderly NSCLC, carboplatin and 
weekly paclitaxel was found to be superior with monotherapy (19), however, was also 
reported severe toxicity with 4.4% toxic deaths. Cisplatin plus docetaxel failed to 
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demonstrate any survival advantage compare with docetaxel monotherapy (20). 
Pemetrexed is a more effective treatment for NSqNSCLC than docetaxel and causes 
significantly fewer adverse events (3, 5), and adding bevacizumab to the standard 
chemotherapy is expected to have additional beneficial effects against NSqNSCLC. 
Therefore, a number of prospective studies of pemetrexed or pemetrexed plus 
bevacizumab for elderly NSqNSCLC patients have been conducted, as shown in 
Supplement Table 1 (4, 21-23). Pemetrexed plus bevacizumab tended to produce better 
outcomes than pemetrexed in terms of the response rate (25-55% vs. 13-25%) and 
progression-free survival (4.8-5.5 months vs. 3.3-5.4 months). On the other hand, 
pemetrexed tended to produce better outcomes than pemetrexed plus bevacizumab in 
terms of overall survival (16.0-18.2 months vs. 11.6-16.4 months). One possible reason 
for these findings is that the combination chemotherapy was too toxic for elderly 
patients because of their decreased physical fitness and organ function and so did not 
result in longer overall survival. However, pemetrexed tends to be associated with a 
higher frequency of grade 3 or 4 neutropenia (29-39% vs. 21-25%) than pemetrexed 
plus bevacizumab, although that was not the case in the present study, and it is difficult 
to compare the outcomes of prospective studies conducted in different situations; 
therefore, a randomized controlled study is needed.  
In the present study, which directly compared the efficacy of pemetrexed and 
pemetrexed plus bevacizumab, the frequencies of grade 3 or 4 neutropenia were higher 
in the pemetrexed plus bevacizumab group (20% and 55%, respectively), which 
indicated that the combination treatment had stronger side effects than the monotherapy. 
Such direct intergroup comparisons are important. Thus, our study is meaningful, as it is 
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the first to directly compare the outcomes of pemetrexed and pemetrexed plus 
bevacizumab.  
Regarding progression-free survival, we did not detect any difference between 
the two groups. So, why was there no intergroup difference in progression-free 
survival? In the current study, the case groups were designed based on the assumption 
that the expected median progression-free survival periods of the pemetrexed group and 
pemetrexed plus bevacizumab group were 3.3 months and 7.4 months, respectively; 
however, the actual median progression-free survival period was 5 to 6 months in both 
groups. As shown in Figure 3, the combination treatment caused tumor shrinkage, 
which seemed to lead to an extension of the progression-free survival period. Looking 
at the relationship between tumor shrinkage and progression-free survival, which is 
shown in Figure 4, marked tumor shrinkage and prolonged progression-free survival 
were seen in only one case in the pemetrexed plus bevacizumab group seems to be more 
of an outlier, and tumor shrinkage was not linked to longer progression-free survival in 
almost cases in this group. The current study was still a small number study with only 
40 patients, therefore, the result of our study is not deterministic and it is weak point of 
the study.  
With respect to combination treatment involving platinum doublet 
chemotherapy and bevacizumab in elderly NSqNSCLC patients, no additional effects 
were observed in patients aged ≥70 years in the subset analysis conducted in the 
ECOG4599 trial, and more cases of grade 3 or 4 neutropenia, bleeding, and proteinuria 
were seen in these patients than in those aged <70 (24). In a subset analysis that 
combined the ECOG4599 and PointBreak trials, bevacizumab tended to have weak 
additional effects on OS and progression-free survival, especially in patients aged >75 
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years (25). Although these findings relate to the additional effects of adding 
bevacizumab to platinum chemotherapy, according to the subset analyses of the clinical 
trials conducted to date it seems that bevacizumab has weak additional effects in elderly 
NSqNSCLC patients aged ≥75 years, which agrees with the results of our trial. In recent 
reports, Wakelee HA et al. conducted large randomized phase III trial with or without 
bevacizumab for adjuvant chemotherapy of resected NSCLC (E1505), and addition of 
bevacizumab did not improve overall survival both in all and elderly (>60) cases (26). 
Whereas Xing P et al. suggest bevacizumab containing regimen have clinical benefits 
over a non-bevacizumab regimen in real world study of NSqNSCLC including elderly 
patients (27), and it is also required to carefully evaluate the adaptation of bevacizumab 
from now. 
Regarding toxicities, leukopenia and neutropenia (bone marrow toxicities) 
tended to exhibit high frequencies in the pemetrexed plus bevacizumab group. 
Neutropenia was seen in 80% of cases, and it was classified as grade 3 or 4 in 55% of 
these cases; therefore, attention must be paid to reducing the risk of neutropenia when 
bevacizumab is administered to elderly patients. Bleeding tendency and proteinuria, 
which are characteristics of bevacizumab treatment, did not occur at high frequencies. 
Stomatitis was not observed in any case in the pemetrexed group, whereas it was seen in 
5 patients (25%) in the pemetrexed plus bevacizumab group. One of these cases was 
classified as grade 1 for the first and second cycles, but it worsened to grade 3 in the 
third cycle, and grade 3 anorexia and fatigue occurred concomitantly, which resulted in 
treatment termination in the third cycle. Thus, stomatitis might be an important adverse 
event although it was not examined in other studies in which pemetrexed plus 
bevacizumab was used to treat elderly patients with NSqNSCLC (22, 23).  
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Regarding cost-effectiveness which was secondary endpoint, the total cost of 
treatment in the pemetrexed plus bevacizumab group was significantly higher than the 
total cost of treatment in the pemetrexed group. Because the survival data of two groups 
were similar, it is important point and seems to help our determination in practical 
treatment.  
In conclusion, this was the first prospective randomized study to compare the 
clinical impact of pemetrexed plus bevacizumab with that of pemetrexed in NSqNSCLC 
patients aged ≥75 years. Adding bevacizumab to pemetrexed did not result in improved 
survival in the elderly NSqNSCLC patients. In fact, compared with pemetrexed plus 
bevacizumab, pemetrexed monotherapy had similar effects on survival, but displayed a 
more favorable toxicity profile and was more cost-effective, and thus, might be one of 
the optional regimen for NSqNSCLC patients aged ≥75 years. 
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Table 1. Patient characteristics  
 
Characteristics                 Pem            Pem + Bev           Total 
 
                             N=20            N=20              N=40 
 
                          number (%)         number (%)        number (%) 
 
Gender    
 male  12 (60) 11 (55) 23 (58) 
 female 8  (40) 9 (45) 17 (43) 
 
Age (years)   
 median 77.5 78.5 78.0 
 range  75-82 75-83 75-83 
 
Stage  
 IIIB 0 (0) 1 (5) 1 (3) 
 IV 15 (75) 15 (75) 30 (75) 
 postope recurrence 5 (25) 4 (20) 9 (23) 
 
PS 
 0 5 (25) 6 (30) 11 (28) 
 1 15 (75) 14 (70) 29 (73) 
 
Histology  
 adenocarcinoma 20 (100) 20 (100) 40 (100) 
 large cell carcinoma 0 (0) 0 (0) 0 (0) 
 others 0 (0) 0 (0) 0 (0) 
 
EGFR mutation* 
 yes 3 (15) 4 (20) 30 (18) 
 no 16 (80) 14 (70) 7 (75) 
 unknown 1 (5) 2 (10) 3 (8) 
 
Smoking history 
 yes 12 (60) 10 (50) 22 (55) 
 no 8 (40) 10 (50) 18 (45) 
 
GFR (ml/min.1.73m2) 
median 63 72 67 
 range  37-120 45-98 37-120 
    
*EGFR mutations include exon 19 deletion and exon 21 L858R mutation. Pem: pemetrexed; 
Pem + Bev: pemetrexed plus bevacizumab   
Table 2. Treatment responses 
  n PR SD PD NE RR (%) DCR (%) 
 Pem 20 3 11 4 2 15* 70 
 Pem + Bev 20 11 7 1 1  55* 95 
 *p=0.0146; Pem: pemetrexed; Pem + Bev: pemetrexed plus bevacizumab; PR: partial response; 
SD: stable disease; PD: progressive disease; NE: not evaluable; RR: response rate; DCR: disease 
control rate 
  
Table 3. Toxicities 
 
Adverse event  Pem Pem + Bev         P-value 
 
  All (%) G3/4 (%) All (%) G3/4 (%) All (%) G3/4 (%) 
 
Hematologic 
 Leukopenia 12 (60) 2 (10) 15 (75) 6 (30) 0.500 0.235 
 Neutropenia 13 (65) 4 (20) 16 (80) 11 (55) 0.479 0.050 
 Anemia 18 (90) 4 (20) 19 (95) 1 (5) 1.000 0.342 
 Thrombocytopenia 17 (85) 1 (5) 16 (80) 1 (5) 1.000 1.000 
 
Non-hematologic  
 Nausea 6 (30) 1 (5) 7 (35) 0 (0) 1.000 1.000 
 Vomiting 2 (10) 0 (0) 3 (15) 0 (0) 1.000 1.000 
 Anorexia 12 (60) 1 (5) 15 (75) 1 (5) 0.500 1.000 
 Malaise 14 (70) 0 (0) 17 (85) 0 (0) 0.451 1.000 
 Diarrhea 1 (5) 0 (0) 5 (25) 0 (0) 0.182 1.000 
 Constipation 4 (20) 0 (0) 6 (30) 0 (0) 0.715 1.000 
 Oral mucositis 0 (0) 0 (0) 5 (25) 1 (5)  0.047* 1.000 
 Alopecia 0 (0) 0 (0) 1 (5) 0 (0) 1.000 1.000 
 Exanthema 3 (15) 1 (5) 0 (0) 0 (0) 0.231 1.000 
 Pneumonitis 2 (10) 0 (0) 1 (5) 0 (0) 1.000 1.000 
 Down of PS 1 (5) 1 (5) 1 (5) 1 (5) 1.000 1.000 
 Elevated ALT 13 (65) 1 (5) 16 (80) 0 (0) 0.479 1.000 
 Elevated AST 17 (85) 2 (10) 18 (90) 0 (0) 1.000 0.487 
 Elevated creatinine 7 (35) 1 (5) 8 (40) 0 (0) 1.000 1.000 
 Hyponatremia 10 (50) 4 (20) 18 (90) 2 (10)  0.014* 0.661 
 Hyperkalemia 8 (40) 0 (0) 10 (50) 1 (5) 0.751 1.000 
 Hemosputum 1 (5) 0 (0) 1 (5) 0 (0) 1.000 1.000 
 Proteinuria** 6 (33) 1 (6) 11 (55) 2 (10) 0.201 1.000 
Hypertension 0 (0) 0 (0) 0 (0) 0 (0) 1.000 1.000 
Thrombosis 0 (0) 0 (0) 0 (0) 0 (0) 1.000 1.000 
Hemorrhage 0 (0) 0 (0) 1 (5) 0 (0) 1.000 1.000 
    
 *Significant difference 
 **Proteinuria: “All” include (+), (2+) and (>2+), “G3/4” include (2+) and (>2+) 
 Pem: pemetrexed; Pem + Bev: pemetrexed plus bevacizumab; G3/4: grade 3/4; PS: performance 
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